Third-party tested
CJC-1295 / Ipamorelin
A research blend of Modified GRF(1-29) and Ipamorelin, studied at the GHRH and ghrelin (GHSR-1a) receptors.
Availability: 10 in stock
CJC-1295 / Ipamorelin, by the numbers.
Structural and laboratory facts that define this compound. For laboratory research use only.
Mod GRF(1-29) + Ipamorelin
GHRH(1-29) with 4 substitutions
Selective GHSR-1a pentapeptide
5 mg + 5 mg per vial
How it is studied.
Two complementary pituitary receptor pathways activated simultaneously for synergistic GH pulse enhancement
CJC-1295 (Modified GRF 1-29) is the GHRH receptor agonist component. It binds GHRH-R on pituitary somatotrophs, stimulating cAMP production and GH synthesis. The four DPP-IV-resistant amino acid substitutions extend bioavailability to ~30 minutes, enabling a sustained window of GHRH-R activation per dose.
- GHRH-R agonism — cAMP-mediated GH synthesis
- ~30-minute half-life for time-matched dosing
- Cortisol, thyroid, prolactin unaffected
Ipamorelin is the GHSR-1a (ghrelin receptor) agonist component. It binds a distinct receptor population on somatotrophs via a phospholipase C / IP3 intracellular pathway — separate from the cAMP route used by GHRH. This complementary signaling allows both pathways to be active simultaneously without receptor competition.
- GHSR-1a agonism — PLC/IP3 intracellular pathway
- No cortisol, ACTH, or prolactin co-secretion
- ~2-hour half-life — pulsatile GH release
When GHRH-R and GHSR-1a are activated simultaneously, GH pulse amplitude exceeds what either compound produces alone. Preclinical data show this additive-to-synergistic interaction: each pathway potentiates the other's pituitary response, producing larger GH pulses without proportionally increasing side effects.
- Additive GH pulse amplitude vs either alone
- Somatostatin suppression potentiated by GHSR agonism
- Physiologic pulsatile pattern preserved
Research pathway map
The primary pathways CJC-1295 / Ipamorelin is investigated against in laboratory models.
Compound details.
Storage & handling
Supplied as a lyophilized powder. Store the sealed vial refrigerated at 2–8°C, protected from light and moisture; −20°C for long-term storage. Keep reconstituted material refrigerated.
Eur J Endocrinol · 1998Ipamorelin, the first selective growth hormone secretagogue
Ipamorelin component: original characterization.
Raun K et al., 1998 · PubMed ↗Endocrinology · 2005hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats
GRF(1-29) analog research at the pituitary GRF receptor.
Jetté L et al., 2005 · PubMed ↗
